azathioprine has been researched along with Molar, Fourth in 1 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Varela, M | 1 |
| García-Camba, P | 1 |
| Gutiérrez Mosquera, B | 1 |
| García Rosas, S | 1 |
| Lorda, I | 1 |
1 other study available for azathioprine and Molar, Fourth
| Article | Year |
|---|---|
[Delayed development of multiple supernumerary teeth in a patient with juvenile myasthenia gravis treated with azathioprine].
Topics: Azathioprine; Child; Female; Humans; Immunosuppressive Agents; Myasthenia Gravis; Time Factors; Toot | 2014 |